These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35237235)

  • 1. Receptors of Advanced Glycation End Product (RAGE) Suppression Associated With a Preserved Osteogenic Differentiation in Patients With Prediabetes.
    Phimphilai M; Pothacharoen P; Chattipakorn N; Kongtawelert P
    Front Endocrinol (Lausanne); 2022; 13():799872. PubMed ID: 35237235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-Influenced Receptors of Advanced Glycation End Product Overexpression Associated With Osteogenic Differentiation Impairment in Patients With Type 2 Diabetes.
    Phimphilai M; Pothacharoen P; Kongtawelert P
    Front Endocrinol (Lausanne); 2021; 12():726182. PubMed ID: 34512554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.
    Phimphilai M; Pothacharoen P; Kongtawelert P; Chattipakorn N
    J Bone Miner Metab; 2017 Nov; 35(6):631-641. PubMed ID: 27873077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylglyoxal - an advanced glycation end products (AGEs) precursor - Inhibits differentiation of human MSC-derived osteoblasts in vitro independently of receptor for AGEs (RAGE).
    Waqas K; Muller M; Koedam M; El Kadi Y; Zillikens MC; van der Eerden BCJ
    Bone; 2022 Nov; 164():116526. PubMed ID: 35995334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The trajectory of osteoblast progenitor cells in patients with type 2 diabetes and the predictive model for their osteogenic differentiation ability.
    Phimphilai M; Pothacharoen P; Chattipakorn N; Kongtawelert P
    Sci Rep; 2023 Feb; 13(1):2338. PubMed ID: 36759556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary advanced glycated end-products and medicines influence the expression of SIRT1 and DDOST in peripheral mononuclear cells from long-term type 1 diabetes patients.
    Santos-Bezerra DP; Machado-Lima A; Monteiro MB; Admoni SN; Perez RV; Machado CG; Shimizu MH; Cavaleiro AM; Thieme K; Queiroz MS; Machado UF; Giannella-Neto D; Passarelli M; Corrêa-Giannella ML
    Diab Vasc Dis Res; 2018 Jan; 15(1):81-89. PubMed ID: 29027826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study.
    Birukov A; Cuadrat R; Polemiti E; Eichelmann F; Schulze MB
    Cardiovasc Diabetol; 2021 Jun; 20(1):110. PubMed ID: 34176469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes.
    Di Pino A; Urbano F; Zagami RM; Filippello A; Di Mauro S; Piro S; Purrello F; Rabuazzo AM
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1701-9. PubMed ID: 26885882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of a disintegrin and metalloproteinase 10 in peripheral blood mononuclear cells in type 2 diabetes mellitus patients with the acute coronary syndrome: a pilot study.
    Ragavi R; Adole PS; Vinod KV; Pillai AA
    Endocrine; 2022 Sep; 77(3):461-468. PubMed ID: 35877008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of receptors of advanced glycation end products ameliorates diabetic osteogenesis of adipose-derived stem cells through DNA methylation and Wnt signalling pathway.
    Zhang M; Li Y; Rao P; Huang K; Luo D; Cai X; Xiao J
    Cell Prolif; 2018 Oct; 51(5):e12471. PubMed ID: 30014569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum AGEs and sRAGE levels are not related to vascular complications in patients with prediabetes.
    Gateva AT; Assyov YS; Tsakova AD; Kamenov ZA
    Diabetes Metab Syndr; 2019; 13(2):1005-1010. PubMed ID: 31336435
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    López-Díez R; Shen X; Daffu G; Khursheed M; Hu J; Song F; Rosario R; Xu Y; Li Q; Xi X; Zou YS; Li H; Schmidt AM; Yan SF
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1536-1547. PubMed ID: 28642238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications.
    Felicetti F; Aimaretti E; Dal Bello F; Gatti F; Godono A; Saba F; Einaudi G; Collino M; Fagioli F; Aragno M; Brignardello E
    Free Radic Biol Med; 2022 Jan; 178():76-82. PubMed ID: 34856327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
    Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
    Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Glycation End Products, Diabetes, and Bone Strength.
    Yamamoto M; Sugimoto T
    Curr Osteoporos Rep; 2016 Dec; 14(6):320-326. PubMed ID: 27704396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Habitual intake of advanced glycation endproducts is not associated with worse insulin sensitivity, worse beta cell function, or presence of prediabetes or type 2 diabetes: The Maastricht Study.
    Linkens AMA; Eussen SJMP; Houben AJHM; Mari A; Dagnelie PC; Stehouwer CDA; Schalkwijk CG
    Clin Nutr; 2023 Aug; 42(8):1491-1500. PubMed ID: 37302878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling of Serum Amyloid A Through Receptor for Advanced Glycation End Products as a Possible Mechanism for Uremia-Related Atherosclerosis.
    Belmokhtar K; Robert T; Ortillon J; Braconnier A; Vuiblet V; Boulagnon-Rombi C; Diebold MD; Pietrement C; Schmidt AM; Rieu P; Touré F
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):800-9. PubMed ID: 26988587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression.
    Belmokhtar K; Ortillon J; Jaisson S; Massy ZA; Boulagnon Rombi C; Doué M; Maurice P; Fritz G; Gillery P; Schmidt AM; Rieu P; Touré F
    Nephrol Dial Transplant; 2019 Dec; 34(12):2018-2030. PubMed ID: 30778553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt/β-catenin signalling pathway via DNA methylation.
    Li Y; Wang L; Zhang M; Huang K; Yao Z; Rao P; Cai X; Xiao J
    Cell Prolif; 2020 Jun; 53(6):e12834. PubMed ID: 32468637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone microarchitecture, biomechanical properties, and advanced glycation end-products in the proximal femur of adults with type 2 diabetes.
    Karim L; Moulton J; Van Vliet M; Velie K; Robbins A; Malekipour F; Abdeen A; Ayres D; Bouxsein ML
    Bone; 2018 Sep; 114():32-39. PubMed ID: 29857063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.